Unity Biotechnology, Inc. - 10-Q filing on 2018-06-07

Net Loss per Common Share (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of Reconciliation of Numerators and Denominators Used In Computing Net Loss From Continuing Operations Per Share

A reconciliation of the numerators and denominators used in computing net loss from continuing operations per share is as follows (in thousands, except per share amounts):

	March 31,
	2018			2017
Numerator:
Net loss	$	(16,133	)	$	(8,934	)
Denominator:
Weighted average number of shares outstanding—basic and diluted		3,437,345			3,079,551
Net loss per share—basic and diluted	$	(4.69	)	$	(2.90	)

Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Per Share

Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:

	Three Months Ended March 31,
	2018		2017
Convertible preferred stock		31,750,297		25,280,436
Options to purchase common stock		4,433,459		2,332,221
Early exercised common stock subject to future vesting		1,058,270		1,199,098
Restricted stock accounted for as options		625,084		—
Warrants to purchase convertible preferred stock		763,501		763,501
Warrants to purchase common stock		96,610		96,610
Total		38,727,221		29,671,866